微创与开放胰十二指肠切除术治疗胰腺导管腺癌的围术期与肿瘤学结局:荟萃分析
该荟萃分析比较微创与开放胰十二指肠切除术在胰腺导管腺癌患者中的结局,纳入9项回顾性队列共11242例患者。两组总生存、手术时间、并发症、30天死亡率、静脉切除率、淋巴结检出数及阳性率无显著差异,但微创组无病生存、辅助化疗启动时间、住院时间和阴性切缘率更优。
要点
- 微创与开放胰十二指肠切除术在胰腺导管腺癌患者中总生存无显著差异。
- 微创组无病生存、辅助化疗启动时间、住院时间和阴性切缘率优于开放组。
- 两组手术时间、并发症、30天死亡率、静脉切除率及淋巴结相关指标无显著差异。
核心结论
- 对于胰腺导管腺癌患者,微创胰十二指肠切除术相比开放手术提供相似甚至更好的围术期、短期和长期肿瘤学结局。
研究设计与样本
- 最终分析纳入9项回顾性队列研究,共11242例患者,其中1377例接受微创胰十二指肠切除术,9865例接受开放胰十二指肠切除术。
主要发现
- 两组患者总生存、手术时间、术后并发症、30天死亡率、静脉切除率、 harvested淋巴结数量及阳性淋巴结率均无显著差异。
- 微创胰十二指肠切除术组在无病生存、辅助化疗启动时间、住院时间和阴性切缘率方面相较开放手术组表现出改善。
临床怎么用
- 在胰腺导管腺癌患者中,微创胰十二指肠切除术可作为开放手术的合理替代,围术期和肿瘤学结局相似或更优。
局限性
- 纳入研究均为回顾性队列,可能存在选择偏倚和混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The outcomes of minimally invasive pancreaticoduodenectomy have not been adequately compared with those of open pancreaticoduodenectomy in patients with pancreatic ductal adenocarcinoma. We performed a meta-analysis to compare the perioperative and oncological outcomes of these two pancreaticoduodenectomy procedures specifically in patients with pancreatic ductal adenocarcinoma. METHODS: Before this study was initiated, a specific protocol was designed and has been registered in PROSEPRO (ID: CRD42020149438). Using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, PubMed, EMBASE, Web of Science, Cochrane Central Register, and ClinicalTrials.gov databases were systematically searched for studies published between January 1994 and October 2019. Overall survival, disease-free survival, and time to commencing adjuvant chemotherapy were the primary endpoint measurements, whereas perioperative and short-term outcomes were the secondary endpoints. RESULTS: The final analysis included 9 retrospective cohorts comprising 11,242 patients (1377 who underwent minimally invasive pancreaticoduodenectomy and 9865 who underwent open pancreaticoduodenectomy). There were no significant differences in the patients' overall survival, operative time, postoperative complications, 30-day mortality, rate of vein resection, number of harvested lymph nodes, or rate of positive lymph nodes between the two approaches. However, disease-free survival, time to starting adjuvant chemotherapy, length of hospital stay, and rate of negative margins in patients who underwent minimally invasive pancreaticoduodenectomy showed improvements relative to those in patients who underwent open surgery. CONCLUSIONS: Minimally invasive pancreaticoduodenectomy provides similar or even improved perioperative, short-term, and long-term oncological outcomes when compared with open pancreaticoduodenectomy for patients with pancreatic ductal adenocarcinoma.
引用
- Sun R, Yu J, Zhang Y, et al. Perioperative and oncological outcomes following minimally invasive versus open pancreaticoduodenectomy for pancreatic duct adenocarcinoma. Surg Endosc. 2020. PMID: 32632485. doi:10.1007/s00464-020-07641-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。